AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23354743 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG + SB
Number of subjects: 96
Study 23354743 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (2.78 μm, 50 mJ, 30 Hz, 1.5 W, 4.5 J/cm(2)) + SE
Number of subjects: 96
Study 23354743 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG + SB
Number of subjects: 96
Study 21913014 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR-based cancer recovery and wellness program
Number of subjects: 68
Study 21913014 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 68
Study 20618247 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 30
Study 20618247 — intervention group
Group type: COMPARATOR
Intervention: Depot medroxyprogesterone acetate (MPA)
Number of subjects: 30
Study 17652689 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 0
Study 17652689 — intervention group
Group type: COMPARATOR
Intervention: Control (no aminophylline)
Number of subjects: 0
Study 16054554 — intervention group
Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 62
Study 16054554 — intervention group
Group type: COMPARATOR
Intervention: Traditional one-to-one care
Number of subjects: 62
Study 12143912 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct switch to olanzapine (10 mg/day for 6 weeks)
Number of subjects: 108
Study 12143912 — intervention group
Group type: EXPERIMENTAL
Intervention: Start‐taper switch to olanzapine (10 mg/day for 6 weeks) with decreasing doses of usual antipsychotic for first 2 weeks
Number of subjects: 108
Study 12143912 — intervention group
Group type: COMPARATOR
Intervention: Both switch techniques
Number of subjects: 108
Study 10201422 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day mianserin
Number of subjects: 100
Study 10201422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7784029 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured amniotic fluid index (AFI) on admission
Number of subjects: 447
Study 7784029 — intervention group
Group type: COMPARATOR
Intervention: No sonographic assessment of amniotic fluid (AF) volume
Number of subjects: 447
Study 2213394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (0.15 mg/kg/dose)
Number of subjects: 40
Study 2213394 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 40
Study 468583 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (3x5000 IU, starting 2 hours preoperatively)
Number of subjects: 1069
Study 468583 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dextran (3x500 ml of 6% dextran 70)
Number of subjects: 1069
Study 31563627 — intervention group
Group type: EXPERIMENTAL
Intervention: Early colonoscopy (within 24 hours)
Number of subjects: 170
Study 31563627 — intervention group
Group type: COMPARATOR
Intervention: Elective colonoscopy (24-96 hours)
Number of subjects: 170
Study 31464771 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB) procedures
Number of subjects: 0
Study 31464771 — intervention group
Group type: EXPERIMENTAL
Intervention: Total arterial revascularization using composite bilateral internal mammary artery-Y-conduits
Number of subjects: 0
Study 31464771 — intervention group
Group type: COMPARATOR
Intervention: Open vein-graft harvesting
Number of subjects: 0
Study 31464771 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic vein-graft harvesting
Number of subjects: 0
Study 28122717 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) - 7 × 1 min at 85% maximal aerobic power output, separated by 1 min of recovery
Number of subjects: 19
Study 28122717 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 19
Study 28122717 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 19
Study 25884325 — intervention group
Group type: EXPERIMENTAL
Intervention: CTI+PVI ablation (group 2)
Number of subjects: 216
Study 25884325 — intervention group
Group type: COMPARATOR
Intervention: CTI alone (group 1)
Number of subjects: 216
Study 25884325 — intervention group
Group type: EXPERIMENTAL
Intervention: CTI+PVI ablation (group 2) in patients aged ≥55
Number of subjects: 216
Study 25884325 — intervention group
Group type: COMPARATOR
Intervention: CTI alone (group 1) in patients aged ≥55
Number of subjects: 216
Study 25884325 — intervention group
Group type: EXPERIMENTAL
Intervention: CTI+PVI ablation (group 2) in patients aged <55
Number of subjects: 216
Study 25884325 — intervention group
Group type: COMPARATOR
Intervention: CTI alone (group 1) in patients aged <55
Number of subjects: 216
Study 24069230 — intervention group
Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) 12 mg
Number of subjects: 23
Study 24069230 — intervention group
Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) 24 mg
Number of subjects: 23
Study 24069230 — intervention group
Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) 48 mg
Number of subjects: 23
Study 24069230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21840601 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.5 mg capsules
Number of subjects: 0
Study 21840601 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 5 mg capsules
Number of subjects: 0
Study 21840601 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus test formulations
Number of subjects: 0
Study 19150378 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal 7-valent pneumococcal conjugate vaccine (7vPCV)
Number of subjects: 0
Study 19150378 — intervention group
Group type: COMPARATOR
Intervention: Control group (7vPCV at 1 and 2 months of age only)
Number of subjects: 0
Study 18044435 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose, vaccinated once at reimplant (day 42)
Number of subjects: 608
Study 18044435 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses, vaccinated on arrival (day 0) and again at reimplant (day 42)
Number of subjects: 608
Study 18044435 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses, vaccinated on arrival (day 0), on day 21, and again at reimplant (day 42)
Number of subjects: 608
Study 18044435 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated external controls
Number of subjects: 608
Study 15761083 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in supine posture within a lower body negative pressure (LBNP) chamber for 45 min/day, 6 days/week.
Number of subjects: 24
Study 15761083 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control (Con) group.
Number of subjects: 24
Study 12474317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone training
Number of subjects: 44
Study 12474317 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoneme training
Number of subjects: 44
Study 12474317 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 9872488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30‐60 mg/day) for mild to moderate hypertension for at least 1 year
Number of subjects: 85
Study 9872488 — intervention group
Group type: COMPARATOR
Intervention: Normotensive women (Control group)
Number of subjects: 85
Study 7646404 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermeasures including repeated LBNP sequences and physical training from the 8th until the 28th day.
Number of subjects: 12
Study 7646404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no countermeasures).
Number of subjects: 12
Study 2642620 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation/imagery audiotape intervention
Number of subjects: 0
Study 2642620 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8813 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 12
Study 8813 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 12
Study 8813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30943962 — intervention group
Group type: EXPERIMENTAL
Intervention: App with detailed feedback (n = 231)
Number of subjects: 463
Study 30943962 — intervention group
Group type: COMPARATOR
Intervention: App without detailed feedback (n = 232)
Number of subjects: 463
Study 30943962 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and intensive users of the app
Number of subjects: 463
Study 30943962 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-users of the app
Number of subjects: 463
Study 30943962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 463
Study 28393816 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic pluggers
Number of subjects: 38
Study 28393816 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentulospirals
Number of subjects: 38
Study 28393816 — intervention group
Group type: EXPERIMENTAL
Intervention: NaviTips
Number of subjects: 38
Study 25068676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer group
Number of subjects: 84
Study 25068676 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 23542611 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg/m2 epratuzumab
Number of subjects: 90
Study 23542611 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 mg/m2 epratuzumab
Number of subjects: 90
Study 23542611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 23542611 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg/m2 epratuzumab in SL0006
Number of subjects: 90
Study 21741309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity therapy
Number of subjects: 441
Study 21741309 — intervention group
Group type: COMPARATOR
Intervention: Client‐centred care
Number of subjects: 441
Study 21741309 — intervention group
Group type: COMPARATOR
Intervention: Standard palliative care
Number of subjects: 441
Study 19826285 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 4 or more times/week
Number of subjects: 90
Study 19826285 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 3 to 4 times/week
Number of subjects: 90
Study 19826285 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise less than 2 times/week
Number of subjects: 90
Study 19826285 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 90
Study 16713070 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 80
Study 16713070 — intervention group
Group type: COMPARATOR
Intervention: Open prostatectomy (OP)
Number of subjects: 80
Study 16713070 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP) and Open prostatectomy (OP)
Number of subjects: 80
Study 15001257 — intervention group
Group type: COMPARATOR
Intervention: EBRT + PCV (non-BUdR patients)
Number of subjects: 268
Study 15001257 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT/BUdR + PCV (BUdR patients)
Number of subjects: 268
Study 11337625 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and bupivacaine combination
Number of subjects: 160
Study 11337625 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 160
Study 9218185 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming training
Number of subjects: 18
Study 9218185 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 7955255 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RVVO
Number of subjects: 20
Study 7955255 — intervention group
Group type: COMPARATOR
Intervention: Age-matched healthy subjects
Number of subjects: 20
Study 3310586 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine HCl (816 ± 103 mg daily)
Number of subjects: 45
Study 3310586 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (120 mg daily)
Number of subjects: 45
Study 3310586 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine HCl (800 mg daily)
Number of subjects: 45
Study 3310586 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide (600 mg daily)
Number of subjects: 45
Study 29895491 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 140 mg, thrice daily for 45 days
Number of subjects: 40
Study 29895491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28539413 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfers (UCT) of 10,000 West African Financial Community of Africa francs (∼US$17) provided monthly from July to November over 2 years (2013 and 2014).
Number of subjects: 32
Study 28539413 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 32
Study 26288091 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Hemodiafiltration (HDF)
Number of subjects: 714
Study 26288091 — intervention group
Group type: COMPARATOR
Intervention: Low-flux Hemodialysis (HD)
Number of subjects: 714
Study 24024358 — intervention group
Group type: EXPERIMENTAL
Intervention: 1990 coal ban
Number of subjects: 0
Study 24024358 — intervention group
Group type: EXPERIMENTAL
Intervention: 1995 coal ban
Number of subjects: 0
Study 24024358 — intervention group
Group type: EXPERIMENTAL
Intervention: 1998 coal ban
Number of subjects: 0
Study 20308169 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 1.0 microg/kg load or DEX 0.5 microg/kg load
Number of subjects: 55
Study 20308169 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX (both dosages)
Number of subjects: 55
Study 20308169 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX
Number of subjects: 55
Study 20308169 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (MDZ)
Number of subjects: 55
Study 20308169 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 55
Study 18447212 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 75
Study 18447212 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (Baihui and Yintang points)
Number of subjects: 75
Study 18447212 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus Fluoxetine
Number of subjects: 75
Study 16373776 — intervention group
Group type: EXPERIMENTAL
Intervention: Internally cooled electrode
Number of subjects: 74
Study 16373776 — intervention group
Group type: COMPARATOR
Intervention: Expandable electrode
Number of subjects: 74
Study 12690216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (target plasma level 0.4 ng/mL)
Number of subjects: 10
Study 12690216 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (target plasma level 0.3 microg/mL)
Number of subjects: 10
Study 12690216 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine plus dexmedetomidine (target plasma levels of 0.3 microg/mL and 0.4 ng/mL)
Number of subjects: 10
Study 12690216 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 10
Study 11064625 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 2 micrograms kg‐1
Number of subjects: 60
Study 11064625 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 4 micrograms kg‐1
Number of subjects: 60
Study 11064625 — intervention group
Group type: COMPARATOR
Intervention: succinylcholine 1 mg kg‐1
Number of subjects: 60
Study 8729586 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 0
Study 8729586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1575006 — intervention group
Group type: EXPERIMENTAL
Intervention: TIA group
Number of subjects: 101
Study 1575006 — intervention group
Group type: COMPARATOR
Intervention: Minor stroke group
Number of subjects: 101
Study 4006376 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 10
Study 4006376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29171139 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 1 mg
Number of subjects: 39
Study 29171139 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 39
Study 29171139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 27643296 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg + Amlodipine 5 mg (L/A group)
Number of subjects: 220
Study 27643296 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg + Hydrochlorothiazide 12.5 mg (L/H group)
Number of subjects: 220
Study 27643296 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg + Amlodipine 100 mg (L/A group)
Number of subjects: 220
Study 27643296 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg + Hydrochlorothiazide 100 mg (L/H group)
Number of subjects: 220
Study 23477573 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrasound exposure
Number of subjects: 54
Study 23477573 — intervention group
Group type: COMPARATOR
Intervention: Sham infrasound exposure
Number of subjects: 54
Study 23477573 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-expectancy group
Number of subjects: 54
Study 23136163 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus MVR
Number of subjects: 73
Study 23136163 — intervention group
Group type: COMPARATOR
Intervention: CABG only
Number of subjects: 73
Study 20336076 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 52
Study 20336076 — intervention group
Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 52
Study 18762494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray with counseling for 8 weeks
Number of subjects: 40
Study 18762494 — intervention group
Group type: COMPARATOR
Intervention: Weekly counseling alone for 8 weeks
Number of subjects: 40
Study 15983465 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil infusion (30-min duration)
Number of subjects: 16
Study 15983465 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (30-min duration)
Number of subjects: 16
Study 15983465 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 16
Study 15983465 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious thermal heat
Number of subjects: 16
Study 12954254 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 0
Study 12954254 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 0
Study 12365120 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drainage
Number of subjects: 440
Study 12365120 — intervention group
Group type: COMPARATOR
Intervention: Non-drainage
Number of subjects: 440
Study 9058355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (brief 10-min study intervention)
Number of subjects: 90
Study 9058355 — intervention group
Group type: COMPARATOR
Intervention: Control (pooled participants)
Number of subjects: 90
Study 9058355 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tobacco use variables (Fagerstrom Test for Nicotine Dependence)
Number of subjects: 90
Study 9058355 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of readiness to quit smoking
Number of subjects: 90
Study 2067505 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 10 micrograms
Number of subjects: 30
Study 2067505 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 micrograms
Number of subjects: 30
Study 2067505 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 10 micrograms
Number of subjects: 30
Study 7049584 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol alone
Number of subjects: 32
Study 7049584 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol + hydrochlorothiazide/amiloride diuretic
Number of subjects: 32
Study 7049584 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide/amiloride diuretic
Number of subjects: 32
Study 31984646 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 280
Study 31984646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 31082899 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 123
Study 31082899 — intervention group
Group type: COMPARATOR
Intervention: Standard wound closure
Number of subjects: 123
Study 28241153 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide
Number of subjects: 94
Study 28241153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 28241153 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Magnesium oxide and Placebo
Number of subjects: 94
Study 26426636 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic radiation force impulse (ARFI) technique measuring shear wave velocity (SWV) at baseline and predetermined time points (1 week, 6 months, and 12 months after transplantation)
Number of subjects: 91
Study 26426636 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic radiation force impulse (ARFI) technique measuring shear wave velocity (SWV)
Number of subjects: 91
Study 23260805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 130
Study 21424274 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill running (DH1)
Number of subjects: 12
Study 21424274 — intervention group
Group type: COMPARATOR
Intervention: Level run (L)
Number of subjects: 12
Study 21424274 — intervention group
Group type: COMPARATOR
Intervention: Downhill running (DH2)
Number of subjects: 12
Study 19862985 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Lumbar Fusion (PLF)
Number of subjects: 30
Study 19862985 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Lumbar Interbody Fusion (PLIF)
Number of subjects: 30
Study 17762365 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP(ex) exercise (40‐min interval at 40‐80% pre‐bed rest VO2peak, 55 +/- 4 mm Hg), 6 d.wk(‐1)
Number of subjects: 16
Study 17762365 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) with no exercise
Number of subjects: 16
Study 15046404 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (lavender essential oil with inert carrier oil)
Number of subjects: 42
Study 15046404 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage alone (inert carrier oil only)
Number of subjects: 42